Checkpoint Therapeutics (CKPT) News Today $2.22 +0.04 (+1.83%) (As of 10/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Bodycam Footage Shows Influencer Therapist's 2023 DUI Arrest At NJ Town's Sobriety CheckpointOctober 4 at 11:01 PM | msn.comMetabolic reprogramming of T cells may enhance checkpoint inhibitor therapySeptember 26, 2024 | msn.comBuy Rating Justified by Promising Efficacy of Checkpoint’s Cosibelimab in Clinical TrialsSeptember 17, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Checkpoint Therapeutics (NASDAQ:CKPT)HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday.September 16, 2024 | marketbeat.comCheckpoint Therapeutics Presents Cosibelimab Longer-Term Results In Advanced CSCCSeptember 16, 2024 | markets.businessinsider.comCheckpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024September 16, 2024 | globenewswire.comCharlotte Airport Checkpoint C closing Thursday for constructionSeptember 6, 2024 | yahoo.comCheckpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comCLT Airport Checkpoint C closing, new American counters open in next step of expansionSeptember 4, 2024 | yahoo.comCCL Label Debuts Innovative RFID Solutions at Labelexpo 2024 with Checkpoint SystemsAugust 27, 2024 | tmcnet.comEMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma ModelAugust 20, 2024 | businesswire.comCheckpoint Therapeutics files secondary offering of up to 5.9M sharesAugust 20, 2024 | msn.comVanguard Group Inc. Acquires 369,586 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)Vanguard Group Inc. grew its holdings in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) by 67.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 917,894 shares of the comAugust 20, 2024 | marketbeat.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest UpdateCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totalling 4,230,000 shares, a growth of 7.4% from the July 15th total of 3,940,000 shares. Based on an average daily volume of 421,200 shares, the short-interest ratio is presently 10.0 days. Approximately 13.9% of the company's shares are short sold.August 19, 2024 | marketbeat.comBurbank Police to Conduct DUI Checkpoint on SaturdayAugust 16, 2024 | msn.comQ3 2024 Earnings Estimate for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Issued By HC WainwrightCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) - HC Wainwright reduced their Q3 2024 earnings per share estimates for Checkpoint Therapeutics in a research note issued on Monday, August 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.51)August 15, 2024 | marketbeat.comFortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 14, 2024 | finanznachrichten.deIndividual investors account for 57% of Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) ownership, while public companies account for 9.8%August 14, 2024 | finance.yahoo.comCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesAugust 14, 2024 | finanznachrichten.deCheckpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesAugust 12, 2024 | globenewswire.comCheckpoint Therapeutics Shares Rise After FDA Accepts Resubmission of CosibelimabJuly 25, 2024 | marketwatch.comCheckpoint Therapeutics Says FDA Accepted BLA Resubmission Of CosibelimabJuly 25, 2024 | markets.businessinsider.comCheckpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaJuly 25, 2024 | globenewswire.comGC Cell and Checkpoint Therapeutics Advance Collaborative Cancer ResearchJuly 15, 2024 | globenewswire.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Down 6.1% in JuneCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of a large decrease in short interest in June. As of June 15th, there was short interest totalling 3,820,000 shares, a decrease of 6.1% from the May 31st total of 4,070,000 shares. Approximately 13.1% of the shares of the company are sold short. Based on an average daily trading volume, of 377,200 shares, the days-to-cover ratio is currently 10.1 days.July 3, 2024 | marketbeat.comCheckpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 13,038 SharesJune 29, 2024 | insidertrades.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $26,858.28 in StockCheckpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 13,038 shares of the business's stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total value of $26,858.28. Following the sale, the chief financial officer now directly owns 672,186 shares in the company, valued at approximately $1,384,703.16. The sale was disclosed in a legal filing with the SEC, which is available through this link.June 28, 2024 | marketbeat.comCheckpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionJune 24, 2024 | globenewswire.comCHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 5, 2024 | globenewswire.comCKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPTJune 3, 2024 | globenewswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)June 3, 2024 | businesswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointJune 3, 2024 | globenewswire.comCKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 3, 2024 | globenewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointMay 31, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTMay 30, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 30, 2024 | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPTMay 29, 2024 | prnewswire.comCheckpoint Zoo Documentary Poster Sets Up A 2022 Ukrainian Animal Rescue StoryMay 29, 2024 | msn.comIMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 28, 2024 | markets.businessinsider.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 28, 2024 | prnewswire.comUPCOMING DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 27, 2024 | markets.businessinsider.com2 Arrested For Driving Under The Influence, 32 Ticketed At CheckpointMay 26, 2024 | sfgate.comFINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 24, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 24, 2024 | prnewswire.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 23, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTMay 22, 2024 | prnewswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPTMay 22, 2024 | prnewswire.comUPCOMING CKPT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Checkpoint Therapeutics, Inc. Investors to Join the Class Action Lawsuit!May 20, 2024 | stockhouse.com Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Next opportunity for crypto millions (Ad)October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere… Go here to discover the coin that could define this historic bull run with gains kicking off this mo CKPT Media Mentions By Week CKPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CKPT News Sentiment▼-0.180.54▲Average Medical News Sentiment CKPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CKPT Articles This Week▼13▲CKPT Articles Average Week Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Leap Therapeutics News Today Korro Bio News Today Aurora Cannabis News Today Esperion Therapeutics News Today Voyager Therapeutics News Today Inozyme Pharma News Today Kamada News Today UroGen Pharma News Today Design Therapeutics News Today Lexeo Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CKPT) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
